News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Champions Biotechnology, Inc. (CSBR) Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing


7/16/2009 12:15:38 PM

IT News Online -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Do-Coop Technologies Ltd. of Israel for development of a more soluble form of SG410, its Benzoylphenylurea (BPU) sulfur analog compound. SG410, an in-licensed compound, is the first agent in Champions' drug development pipeline. Using Neowater(R), a novel proprietary water-based nanotechnology, Do-Coop has been able to improve the solubility and activity of SG410.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES